Cargando…
Beta-Hydroxybutyrate, Friend or Foe for Stressed Hearts
One of the characteristics of the failing human heart is a significant alteration in its energy metabolism. Recently, a ketone body, β-hydroxybutyrate (β-OHB) has been implicated in the failing heart’s energy metabolism as an alternative “fuel source.” Utilization of β-OHB in the failing heart incre...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932950/ https://www.ncbi.nlm.nih.gov/pubmed/35309549 http://dx.doi.org/10.3389/fragi.2021.681513 |
_version_ | 1784671541279064064 |
---|---|
author | Chu, Yuxin Zhang, Cheng Xie, Min |
author_facet | Chu, Yuxin Zhang, Cheng Xie, Min |
author_sort | Chu, Yuxin |
collection | PubMed |
description | One of the characteristics of the failing human heart is a significant alteration in its energy metabolism. Recently, a ketone body, β-hydroxybutyrate (β-OHB) has been implicated in the failing heart’s energy metabolism as an alternative “fuel source.” Utilization of β-OHB in the failing heart increases, and this serves as a “fuel switch” that has been demonstrated to become an adaptive response to stress during the heart failure progression in both diabetic and non-diabetic patients. In addition to serving as an alternative “fuel,” β-OHB represents a signaling molecule that acts as an endogenous histone deacetylase (HDAC) inhibitor. It can increase histone acetylation or lysine acetylation of other signaling molecules. β-OHB has been shown to decrease the production of reactive oxygen species and activate autophagy. Moreover, β-OHB works as an NLR family pyrin domain-containing protein 3 (Nlrp3) inflammasome inhibitor and reduces Nlrp3-mediated inflammatory responses. It has also been reported that β-OHB plays a role in transcriptional or post-translational regulations of various genes’ expression. Increasing β-OHB levels prior to ischemia/reperfusion injury results in a reduced infarct size in rodents, likely due to the signaling function of β-OHB in addition to its role in providing energy. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have been shown to exert strong beneficial effects on the cardiovascular system. They are also capable of increasing the production of β-OHB, which may partially explain their clinical efficacy. Despite all of the beneficial effects of β-OHB, some studies have shown detrimental effects of long-term exposure to β-OHB. Furthermore, not all means of increasing β-OHB levels in the heart are equally effective in treating heart failure. The best timing and therapeutic strategies for the delivery of β-OHB to treat heart disease are unknown and yet to be determined. In this review, we focus on the crucial role of ketone bodies, particularly β-OHB, as both an energy source and a signaling molecule in the stressed heart and the overall therapeutic potential of this compound for cardiovascular diseases. |
format | Online Article Text |
id | pubmed-8932950 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89329502022-03-18 Beta-Hydroxybutyrate, Friend or Foe for Stressed Hearts Chu, Yuxin Zhang, Cheng Xie, Min Front Aging Aging One of the characteristics of the failing human heart is a significant alteration in its energy metabolism. Recently, a ketone body, β-hydroxybutyrate (β-OHB) has been implicated in the failing heart’s energy metabolism as an alternative “fuel source.” Utilization of β-OHB in the failing heart increases, and this serves as a “fuel switch” that has been demonstrated to become an adaptive response to stress during the heart failure progression in both diabetic and non-diabetic patients. In addition to serving as an alternative “fuel,” β-OHB represents a signaling molecule that acts as an endogenous histone deacetylase (HDAC) inhibitor. It can increase histone acetylation or lysine acetylation of other signaling molecules. β-OHB has been shown to decrease the production of reactive oxygen species and activate autophagy. Moreover, β-OHB works as an NLR family pyrin domain-containing protein 3 (Nlrp3) inflammasome inhibitor and reduces Nlrp3-mediated inflammatory responses. It has also been reported that β-OHB plays a role in transcriptional or post-translational regulations of various genes’ expression. Increasing β-OHB levels prior to ischemia/reperfusion injury results in a reduced infarct size in rodents, likely due to the signaling function of β-OHB in addition to its role in providing energy. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have been shown to exert strong beneficial effects on the cardiovascular system. They are also capable of increasing the production of β-OHB, which may partially explain their clinical efficacy. Despite all of the beneficial effects of β-OHB, some studies have shown detrimental effects of long-term exposure to β-OHB. Furthermore, not all means of increasing β-OHB levels in the heart are equally effective in treating heart failure. The best timing and therapeutic strategies for the delivery of β-OHB to treat heart disease are unknown and yet to be determined. In this review, we focus on the crucial role of ketone bodies, particularly β-OHB, as both an energy source and a signaling molecule in the stressed heart and the overall therapeutic potential of this compound for cardiovascular diseases. Frontiers Media S.A. 2021-06-08 /pmc/articles/PMC8932950/ /pubmed/35309549 http://dx.doi.org/10.3389/fragi.2021.681513 Text en Copyright © 2021 Chu, Zhang and Xie. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Aging Chu, Yuxin Zhang, Cheng Xie, Min Beta-Hydroxybutyrate, Friend or Foe for Stressed Hearts |
title | Beta-Hydroxybutyrate, Friend or Foe for Stressed Hearts |
title_full | Beta-Hydroxybutyrate, Friend or Foe for Stressed Hearts |
title_fullStr | Beta-Hydroxybutyrate, Friend or Foe for Stressed Hearts |
title_full_unstemmed | Beta-Hydroxybutyrate, Friend or Foe for Stressed Hearts |
title_short | Beta-Hydroxybutyrate, Friend or Foe for Stressed Hearts |
title_sort | beta-hydroxybutyrate, friend or foe for stressed hearts |
topic | Aging |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932950/ https://www.ncbi.nlm.nih.gov/pubmed/35309549 http://dx.doi.org/10.3389/fragi.2021.681513 |
work_keys_str_mv | AT chuyuxin betahydroxybutyratefriendorfoeforstressedhearts AT zhangcheng betahydroxybutyratefriendorfoeforstressedhearts AT xiemin betahydroxybutyratefriendorfoeforstressedhearts |